文献速递泌尿男性生殖肿瘤

聚(ADP-核糖)聚合酶抑制剂在同源重组修复基因突变转移性去势抵抗性前列腺癌中各基因的疗效:美国食品药品监督管理局汇总分析

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
PubMed 文献 · J Clin Oncol · 2024-03-14

该汇总分析整合多项PARPi治疗mCRPC试验的患者水平数据,按个体HRR基因计算rPFS和OS的HR。在一线mCRPC三项随机试验池中,BRCA1m、BRCA2m、CDK12m和PALB2m患者从PARPi联合ARPI中获益似乎最大,而ATMm和CHEK2m患者未见获益。

要点

  • BRCA2m患者rPFS HR 0.31(95%CI 0.23-0.42),OS HR 0.66(95%CI 0.49-0.89)。
  • CDK12m患者rPFS HR 0.50(95%CI 0.32-0.80),OS HR 0.63(95%CI 0.39-0.99)。
  • ATMm患者rPFS HR 1.05(95%CI 0.74-1.49),OS HR 1.18(95%CI 0.82-1.71)。

核心结论

  • 在该汇总分析中,BRCA1m、BRCA2m、CDK12m和PALB2m患者从PARPi中获益似乎最大。
  • 鉴于该探索性分析的局限性,CHEK2m或ATMm患者中PARPi似乎缺乏获益,应在未来临床试验中进一步探索。

研究设计与样本

  • 对多项PARPi治疗mCRPC试验进行患者水平数据汇总分析,纳入报告个体HRR基因突变状态的试验。
  • 选择在一线mCRPC所有PARPi随机试验中均有可用数据的任何HRR基因。
  • 在一线mCRPC三项随机试验池中,使用Kaplan-Meier估计和Cox比例风险模型计算PARPi联合ARPI相对安慰剂联合ARPI的rPFS(盲态独立审阅)和OS的HR(95%CI)。

主要发现

  • ATMm(N=268):rPFS HR 1.05(95%CI 0.74-1.49),OS HR 1.18(95%CI 0.82-1.71)。
  • BRCA1m(N=64):rPFS HR 0.51(95%CI 0.23-1.1),OS HR 0.74(95%CI 0.34-1.61)。
  • BRCA2m(N=422):rPFS HR 0.31(95%CI 0.23-0.42),OS HR 0.66(95%CI 0.49-0.89)。
  • CDK12m(N=164):rPFS HR 0.50(95%CI 0.32-0.80),OS HR 0.63(95%CI 0.39-0.99)。
  • CHEK2m(N=172):rPFS HR 1.06(95%CI 0.67-1.66),OS HR 1.53(95%CI 0.95-2.46);PALB2m(N=41):rPFS HR 0.52(95%CI 0.23-1.17),OS HR 0.78(95%CI 0.34-1.8)。

局限性

  • 该分析为探索性分析,原文述及其存在局限性。
  • CHEK2m或ATMm患者中PARPi似乎缺乏获益,应在未来临床试验中进一步探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We performed a pooled analysis of multiple trials of poly(ADP-ribose) polymerase inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) to investigate the efficacy of PARPi in each individual homologous recombination repair (HRR) mutated (m) gene. PATIENTS AND METHODS: We pooled patient-level data from trials of PARPi in mCRPC that reported mutation status in individual HRR genes. Any HRR gene with available data across all the randomized trials of PARPi in first-line mCRPC was selected. The hazard ratios (HRs; 95% CI) for radiographic progression-free survival (rPFS; by blinded independent review) and overall survival (OS) of a PARPi plus an androgen receptor pathway inhibitor (ARPI) relative to placebo plus an ARPI in the pool of three randomized trials in first-line mCRPC were calculated using Kaplan-Meier estimates and a Cox proportional hazards model. RESULTS: In ATMm (N = 268), rPFS HR was 1.05 (0.74 to 1.49) and OS HR was 1.18 (0.82 to 1.71). In BRCA1m (N = 64), rPFS HR was 0.51 (0.23 to 1.1) and OS HR was 0.74 (0.34 to 1.61). In BRCA2m (N = 422), rPFS HR was 0.31 (0.23 to 0.42) and OS HR was 0.66 (0.49 to 0.89). In CDK12m (N = 164), rPFS HR was 0.50 (0.32 to 0.80) and OS HR was 0.63 (0.39 to 0.99). In CHEK2m (N = 172), rPFS HR was 1.06 (0.67 to 1.66) and OS HR was 1.53 (0.95 to 2.46). In PALB2m (N = 41) rPFS HR was 0.52 (0.23 to 1.17) and OS HR was 0.78 (0.34 to 1.8). CONCLUSION: In this pooled analysis, benefit from PARPi appeared greatest for patients with BRCA1m, BRCA2m, CDK12m, and PALB2m. Given limitations of this exploratory analysis, the apparent lack of benefit from PARPi in patients with CHEK2m or ATMm should be further explored in future clinical trials.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Fallah J, Xu J, Weinstock C, et al. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis. J Clin Oncol. 2024. PMID: 38484203. doi:10.1200/JCO.23.02105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。